Keunchil Park - Researcher Profile | RDL Research Database

Publications

2 shown

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

Edward B. Garon , Tudor‐Eliade Ciuleanu , Óscar Arrieta +23 more

2014 The Lancet 1263 citations

A review of the benefit–risk profile of gefitinib in Asian patients with advanced non‐small‐cell lung cancer

Keunchil Park , Kōichi Goto

In the majority of these reports, objective response rates of > 25% and disease control rates of > 60% have been described. Treatment with gefitinib resulted in a median time to...

2006 Current Medical Research and Opinion 92 citations

Frequent Co-Authors

Researcher Info

h-index: 2
Publications: 2
Citations: 1,355
Institution: Samsung Medical Center

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0002-4846-7449

Impact Metrics

h-index 2

h-index: Number of publications with at least h citations each.